The number of clinical trials in Russia is decreasing due to problems with finances and intellectual property protection
Russia has a great starting position: capacity and infrastructure. Clinical trials take up 60–70% of the world's total R&D, which amounts to about USD 100 billion. However, over the past 7 years the number of clinical trials in Russia has declined, not increased. What are the reasons for this lag? First of all, these are complex price and reward conditions. Gaps in the regulation of intellectual property rights. To a certain extent, this is a localization problem — Meir Pugatch, Professor, University of Haifa.
Research programmes take a long time. Innovative technology takes 10 to 15 years or even more to develop and get to the market. Long research periods and colossal resources typically in excess of USD 1 billion that go into these studies, make the protection of intellectual property extremely important — Joerg Moeller, Corporate Executive Vice President, Member of the Executive Committee of Bayer AG's Pharmaceutical Division, Head of Global Development, Bayer AG.
In Russia, many projects are conducted in a format of collective development at the junction of commercial players and academic science in the universities. Here we face the lack of a culture of protecting intellectual property rights of scientific groups. Often times, research teams do not have enough resources and they simply ignore timely protection. A negative factor is a KPI development by the regulator, when the scientific teams are evaluated by citation indexes and publications. They chase it and go out into the public field before it's necessary, and lose the opportunity to patent their designs — Vasiliy Ignatiev, CEO, R-Farm.